Bausch+Lomb owner Valeant Pharmaceuticals International has complained to authorities regarding statements made by its latest acquisition target Allergan.
Valeant contacted the Autorite des marches financiers in Quebec and the US Securities and Exchange Commission (SEC) this week, saying Allergan had made ‘false and misleading statements’ regarding Valeant’s business.
Last month Allergan twice rejected acquisition offers from Valeant, which in May 2013 acquired B+L for $8.7bn in cash, and has since published concerns about Valeant in SEC filings. Among these concerns were that B+L ‘appears to be losing market share in pharmaceuticals, lenses and intraocular lens’.
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here